Sanofi at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Sanofi brings 4 presentations to IDWeek 2026 in Washington, and exhibits at Booth 1225, BS 21, BS 22, BS 28. Its program centres on meningococcal vaccination and on protecting infants against RSV. Featured studies compare the MenACWY-TT meningococcal vaccine with MenACWY-CRM in adolescents and test its protection against a hypervirulent serogroup Y strain in circulation.
| Organization | IDWeek 2026 Attendance |
|---|---|
Sanofi Paris, France | |
Global healthcare company developing medicines and vaccines, with teams in some 100 countries. | Booth Exhibiting at Booth 1225, BS 21, BS 22, BS 28 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Thu Oct 22 12:15pm–1:00pm Invasive Meningococcal Disease Across the Lifespan: Changing Epidemiology and Emerging Risk Populations VaccinesGlobal and public health Industry Fri Oct 23 12:15pm–1:00pm The Great Debate: Which Communication Strategy Works Best for Infant RSV Immunization? VaccinesRespiratory infections and COVID-19 Poster Sat Oct 24 12:15pm–1:30pm Exploring Superiority of MenACWY-TT Vaccine Compared to MenACWY-CRM Vaccine in Adolescents – a Post-hoc Analysis. Poster Sat Oct 24 12:15pm–1:30pm Real-World Strains, Real-World Protection: Meningococcal ACWY Conjugate Vaccine (MenACWY-TT) Demonstrates Robust Immunogenicity Against Circulating Hypervirulent Serogroup Y ST-1466 |
Instantly find 20 buyers from Sanofi
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction